菜单
Telephone sharing button Contact Us linkedin sharing button LinkedIn wechat sharing button YouTube wechat sharing button Twitter mailbox sharing button info@wuxibiologics.com
arrow_left sharing button
arrow_right sharing button

Scientific Poster Download

modified on Nov. 3, 2024

This, That, and the Other: Combining Primary, Secondary, and Tertiary Signals with Immune Cell Engagers to Supercharge Anti-Tumor Immunity
Lei Wu, Yaohua Hu, Xia Wang, Yongqing Cheng, Zhaohui Li, Yali Wan, Mengmeng Sun, Tengfei Yu, Xinyan Ji, Wenwen Wang, Shanting Zhang, Yanwen Zhu, Bo Huang, Siwei Nie, Jijie Gu
WuXi Biologics, Shanghai, China

Tapping into the natural T cell activation pathways of TCRs, co-stimulatory molecules, and cytokines, WuXi Biologics has developed a clinical stage anti-CD3 antibody whose binding kinetics balance remarkable efficacy with low cytokine release, co-stimulatory engagers to overcome immune suppression, and cytokine muteins with improved PK and safety to sustainably expand the immune effector cell pool. With these complementary immune cell engager platforms and pharmacology service excellence, we aim to enable clients to discover novel immune cell engagers with clinical prospects.

 

This scientific poster was originally presented during the PEGS EU 2024 conference

Discuss This Poster

To discuss the data in this poster, please complete the form on the following page to connect with our experts.

Connect with our Experts